Home > Neurology > MS Virtual 2020 > Miscellaneous Topics > Amantadine, modafinil, and methylphenidate for MS-related fatigue

Amantadine, modafinil, and methylphenidate for MS-related fatigue


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
MS Virtual 2020
Trial
Phase 3, TRIUMPHANT-MS
For fatigue, one of the most prevalent subjective symptoms in MS patients, methylphenidate, modafinil, and amantadine are commonly prescribed. Substantial evidence supporting their efficacy is however lacking. In the randomised crossover TRIUMPHANT-MS trial, none of these 3 agents was superior to placebo in improving MS-related fatigue, but they did cause more adverse events [1]. The TRIUMPHANT-MS trial compared the efficacy of twice-daily oral methylphenidate, modafinil, and amantadine against each other and placebo. Eligible patients had MS-related fatigue with a Modified Fatigue Impact Scale (MFIS) score of >33. EDSS score at the time of screening ranged from 0.0 to 7.0. A total of 141 adult patients received 1 of 4 treatment sequences: amantadine, placebo, modafinil, methylphenidate; placebo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on